Alkermes PLC logo Roanoke Asset Management Corp NY decreased its position in shares of Alkermes PLC (NASDAQ:ALKS) by 21.8% during the third quarter, according to its most recent 13F filing with the SEC.
Alkermes tested ALKS 5461 in patients with major depressive disorder who haven't been helped by other drugs. At the higher dose, ALKS 5461 improved symptoms of depression -- based on two different scales used by doctors -- compared with placebo.
Alkermes (NASDAQ:ALKS), a biopharmaceutical company that specializes in extended-release drug delivery technology, reported third-quarter results on Nov. 2 and provided investors with an update on its pipeline.
As disclosed in a public form that's filled with the U.S. SEC on 30-11-2016, Michael Landine an insider in Alkermes Plc. and currently SVP - Corp Dev. - Alkermes - Inc., sold shares worth $575,083 U.S. Dollars in the Ireland-based Alkermes Plc. He sold ...